Still haunt­ed by its founder’s scan­dalous past, Kad­mon scores a $75M IPO

Like a num­ber of biotechs these days, Kad­mon had to low­er its price and bump up the num­ber of shares to get its IPO done …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.